April 3rd News: On April 2nd, China Xuyang Group announced that its self-developed caprolactam-to-hexamethylenediamine (HMD) facility completed catalyst loading on March 30th, 2026, laying the foundation for production commencement in April. The facility is expected to achieve an annual output of approximately 30,000 tons in 2026. Chempricehub's analysis of caprolactam shows a bullish-bearish score of 1. The commissioning of China Xuyang Group's caprolactam-to-HMD facility, with an expected annual output of 30,000 tons, will increase demand for caprolactam as a raw material, potentially driving up spot prices. This demand growth is favorable for the market, though the scale is moderate, representing a general positive. For hexamethylenediamine (HMD), the bullish-bearish score is -1. After the facility becomes operational, HMD supply is expected to increase by 30,000 tons, which may lead to oversupply in the market and suppress spot prices. The additional capacity exerts downward pressure on prices, representing a general negative.